Established Unicocell Biomed in 2011 focused on Mesenchymal Stem Cell research as Founder, President and CEO. Listed Unicocell company at emerging stock market in 2015Leading product line CT021 on Osteoarthritis launched Clinical Trail Phase I/II in 2016 and finished phase I in early 2017 under tFDA's guidanceLeading MSC treatment of Chronic Kidney Failure obtained FDA approval on Phase I/II Trial. On 2019 UnicoCell has been publicized on IPO market as the leading stem cell therapeutic company.After stepping out UnicoCell in 2021, CellTech Innovation Studio was raised with another four co-Founders in 2023. The accelerator is focused on creating an Ecosystem in CGT sector and assisting companies and startups toward their success. By the end of 2023, I was invited as the Secretary General of TACT, Taiwan Associate of Cellular Therapy, and further enrolled as part-time assistant professor in Department of Biochemistry and Molecular Biology of Medical College, National Taiwan University.